Review

γδ T cell responses: How many ligands will it take till we know?

David Vermijlen [a],[*], Deborah Gatti [a], Ariadni Kouzeli [b], Teja Rus [b], Matthias Eberl [b],[c],[**]

[a] Department of Pharmacotherapy and Pharmaceutics and Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Belgium
[b] Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
[c] Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom

ARTICLE INFO

ABSTRACT

γδ T cells constitute a sizeable and non-redundant fraction of the total T cell pool in all jawed vertebrates, but in contrast to conventional αβ T cells they are not restricted by classical MHC molecules. Progress in our understanding of the role of γδ T cells in the immune system has been hampered, and is being hampered, by the considerable lack of knowledge regarding the antigens γδ T cells respond to. The past few years have seen a wealth of data regarding the TCR repertoires of distinct γδ T cell populations and a growing list of confirmed and proposed molecules that are recognised by γδ T cells in different species. Yet, the physiological contexts underlying the often restricted TCR usage and the chemical diversity of γδ T cell ligands remain largely unclear, and only few structural studies have confirmed direct ligand recognition by the TCR. We here review the latest progress in the identification and validation of putative γδ T cell ligands and discuss the implications of such findings for γδ T cell responses in health and disease.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Contents

* Corresponding author at: Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium.
** Corresponding author at: Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom.
   E-mail addresses: dvermijl@ulb.ac.be (D. Vermijlen), eberlm@cf.ac.uk (M. Eberl).

1. Introduction: how does it feel, like a complete unknown?

The past three decades have witnessed remarkable progress in our understanding of antigen presentation and the molecular and cellular mechanisms underlying antigen-specific αβ T cell responses, as summarised in this special issue of *Seminars in Cell and Developmental Biology*. The outstanding importance of antigen presentation for biomedical science as a whole of some of the major contributions in the field is best illustrated by the awarding of the Nobel Prizes in Physiology or Medicine for the discovery of the major histocompatibility complex (MHC) in 1980, the principles of overcoming organ transplant rejection in 1990, the definition of MHC restricted immune responses in 1996, and the discovery of dendritic cells (DCs) and their role in adaptive immunity in 2011. Such knowledge is now successfully exploited in the clinic for antigen-specific vaccination against infectious diseases and cancer, and for the induction of immune tolerance in autoimmune disorders.

Set apart from MHC restricted αβ T cells, γδ T cells constitute a sizeable and non-redundant fraction of the total T cell pool in all jawed vertebrates. Although typically portrayed as a minor lymphocyte subset in humans and rodents, γδ T cells may actually exceed >50% of all T cells and thus constitute the dominant T cell population in certain tissues and species, for instance in ruminants and chicken (especially in early life), in the mouse epidermis, and in human blood during microbial infection [1–3]. Moreover, γδ T cells have been implicated in a wide range of immunological scenarios in the healthy organism and in disease [4–6]. However, progress in our understanding of the role of γδ T cells in the immune system has been hampered, and is being hampered, by the considerable lack of knowledge regarding the structures γδ T cells respond to, despite extensive efforts by numerous laboratories since the discovery of γδ T cells in the mid-1980s [7]. In stark contrast to the well-defined presentation of peptide antigens to CD4+ and CD8+ αβ T cells via MHC class II and class I molecules, respectively, and the elucidation of additional pathways leading to the presentation of lipids and metabolites via CD1 family members and the MHC-related protein MR1 [8], there is no consensus as to the class of 'antigens' γδ T cells recognise, and how such antigens are presented. In fact, there is only little evidence that antigens are indeed 'presented' to γδ T cells in the classical sense.

2. The role of the γδ TCR: blowin' in the wind

2.1. Ligand recognition during thymic selection

As in αβ T cells, a diverse TCR repertoire can be generated in γδ T cells by variable (V) gene combinations and formation of V(D)J junctions [6]. γδ T cells are conspicuously different at the TCR level from conventional αβ T cells in that they display characteristic TCR biases with regard to V usage and/or complementarity determining region 3 (CDR3) sequences, depending on the anatomical location and physiological context. Of note, there are no obvious homologies between human and mouse V gene sequences, thus making it difficult to compare mouse and human γδ T cells based on their TCR usage [11,12]. In mice, distinct waves of γδ T cell subsets expressing characteristic Vγ and Vδ combinations populate different organs during embryonic development and display distinct effector functions [4–6]. These early γδ T cells in fact express invariant γδ TCRs, whereas later on in development the TCRs possess polyclonal CDR3 sequences but typically still show biased V chain usages [14].

Representing the prime example of such an invariant TCR, the first γδ T cells to emerge in the murine foetal thymus express a fixed TCR composed of invariant Vγ5Jγ1Cγ1 and invariant Vδ1Dδ2Jδ2 chains (Vγ5/Vδ1 in short; nomenclature according to Heilig and Tonegawa [13]) and migrate to the skin epidermis where they become dendritic epidermal T cells (DETCs) [14]. The next such population arising in the thymus actually carries the same canonical Vδ1Dδ2Jδ2 chain yet combined with an invariant Vγ6Jγ1Cγ1 chain (Vγ6/Vδ1 T cells), and seeds the skin dermis and other tissues [14]. Thus, separate γδ T cell subsets may occupy different sites even within the same organ.

The biases in TCR usage depending on anatomical locations and functions strongly indicate a direct involvement of the TCR, and consequently of tissue-restricted self or non-self ligands, in shaping different γδ T cell compartments and in local immune surveillance and/or pathogen sensing. However, it has been suggested that γδ T cells may also exert major functions in an innate-like, TCR independent manner [15,16]. Such findings seemingly question the physiological relevance of the γδ TCR and the corresponding γδ T cell ligands in certain contexts although it may be technically challenging to exclude simultaneous TCR triggering depending on the experimental conditions [17]. There is also apparently conflicting evidence for the precise role of the γδ TCR in thymic development, especially with regard to the requirement of a possible ligand-dependent positive selection and developmental programming of γδ T cells [18]. Clearly, the role of the γδ TCR is different from the 'conventional' selection of MHC restricted CD4+ and CD8+ T cells, and this role appears to vary greatly across different γδ T cell subsets [6,19–23]. Indeed, in contrast to αβ T cells that leave the thymus as naive antigen-inexperienced T cells, functional maturation and pre-programming of γδ T cells may already occur in the thymus [24,25], with different γδ T cell subsets as marked by particular Vγ usage showing distinct TCR signal strength requirements for their functional differentiation [18,23]. However, the fact that Vγ5/Vδ1 and Vγ6/Vδ1 TCR sequences are present at the DNA level in the foetal thymus of TCRδ$^{-/-}$ mice suggests that the corresponding TCR rearrangements are not necessarily a result of clonal thymic selection [26]. Other cells in the thymus, such as medullary thymic epithelial cells (mTECs), may play an important role in γδ T cell development. Indeed, murine Vγ5/Vδ1 T cell progenitors contribute to the emergence of Aire+ mTECs that in turn foster Skint-1-dependent DETC progenitor maturation and the emergence of an invariant DETC Vγ5Vδ1 repertoire [27]. In addition, Aire may have an inhibitory role in the development of IL-17 producing invariant Vγ6/Vδ1 T cells in the mouse [28].

The majority of human blood γδ T cells express a Vγ9JγPCγ1 chain paired with a Vδ2 chain (Vγ9/Vδ2 T cells; nomenclature according to Lefranc & Rabbitts [29]), while γδ T cells in tissues such as the intestine, skin or liver are enriched in other Vδ and/or Vγ chains [4–6]. The high prevalence of Vγ9/Vδ2 T cells showing a restricted TCR repertoire in the adult peripheral blood has been attributed to extrathymic expansion in response to environmental and pathogenic microbes [30], with a striking prevalence of a single germline-encoded CDR3γ sequence in adults [31,32]. However, functionally programmed Vγ9/Vδ2 T cells expressing a semi-invariant TCR already dominate in second trimester foetal blood, before post-natal microbial exposure [33], therefore arguing against ligand-driven focussing of the TCR repertoire after birth. As for murine foetal Vγ5/Vδ1 T cells, the role of putative TCR ligands in thymic selection of human Vγ9/Vδ2 T cells remains to be investigated, and further studies are clearly needed to address how γδ T cell subsets acquire their TCR and functional specificities.

2.2. Ligand-dependent peripheral expansion

A change in the TCR repertoire, especially of the variable CDR3 region, upon infection or in response to other stimuli can be regarded as evidence of functional involvement of the TCR, and thus cognate TCR-ligand interaction [34,35]. For instance, human Vγ9/Vδ2 T cells expand in numerous microbial infections [3,36].

Fig. 1. Different classes of proposed and confirmed γδ T cell ligands. Examples include classical MHC class I (HLA-B*5802, free HLA heavy chain) and class II molecules (I-E^k, I-A^d), members of the CD1 family (CD1c, CD1d) that may or may not present lipid antigens, MHC and CD1 related molecules (T10/T22, Qa-1, MICA, EPCR), butyrophilin-like molecules (Skint-1, BTN3A1), other surface-bound proteins (hMSH2, EphA2, annexin A2), soluble proteins (HSV-gI, phycoerythrin, histidyl-tRNA synthetase), 'phosphoantigens' (HMB-PP, IPP), haptens (cyanine 3, 4-hydroxy-3-nitrophenyl acetyl) and free peptides (insulin B:9-23 and others).

However, it is not clear whether there is a preferential selection of certain CDR3 regions upon encountering pathogens, especially within the polyclonal CDR3δ repertoire using the Vδ2 gene segment [31,33,37]. γδ T cells also respond towards human cytomegalovirus (CMV), showing striking expansions in the blood of organ transplant recipients [35,38–40]. These expansions are limited to Vδ1$^+$, Vδ3$^+$ and Vδ5$^+$ T cells (often referred to as Vδ2^{neg} T cells) and accompanied by restrictions in the CDR3 repertoire, especially of the CDR3δ using the Vδ3 gene segment [38]. While unfocused polyclonal γδ TCR repertoires are present in γδ T cells derived from term delivery cord blood [34,40], CDR3 repertoires become highly restricted upon congenital CMV infection *in utero*, with a striking enrichment of a public and invariant Vγ8/Vδ1 TCR that contains germline-encoded CDR3γ and CDR3δ [40]. Thus, different human γδ T cell subsets appear to react towards different types of pathogens, and in the case of CMV infection, substantial changes in the CDR3 repertoires strongly indicate an involvement of cognate TCR-ligand interactions. Of note, TCR biases have also been observed within MHC-restricted αβ T cell responses, for instance towards herpes viruses, including CMV [9,10]. Yet, with only a very limited number of γδ TCR ligands and structures defined so far it remains unclear as to how much these antigen-specific αβ TCR biases compare to the highly skewed γδ TCR repertoires [34,35,40].

Clonal selection of particular TCRs is a feature of adaptive immunity shared with αβ T cells and may indicate the generation of γδ T cell memory [34]. Recent studies in mouse models have indeed provided evidence for the existence of memory responses by γδ T cells [41–45], expanding previous observations in primates and in cattle [46–48]. In particular, two groups independently demonstrated an involvement of TCR signalling, presumably as a result of TCR-ligand interactions, in the generation of γδ T cell memory, with preferential enrichments in the usage of specific Vγ and Vδ chains [43,44]. Yet, CDR3 sequences were not investigated in these studies, thus calling for further in-depth analyses of recall responses by γδ T cells. Even more, irrespective of the substantial progress in our understanding of changes in the γδ TCR repertoire during development and as a result of homeostatic or infection/stress-related expansion in the periphery [6,14,34,35,48], there are remarkably few examples of γδ T cell ligands that have been implicated in such processes.

3. Monomorphic yet diverse ligands: down in the groove?

The unexpected discovery of γδ T cells in the mid 1980s immediately posed questions as to the nature of the target antigens these cells recognise. Strikingly, the compounds that have been proposed or confirmed as γδ T cell ligands since then span a staggering range of diverse molecular structures [6,49–52]. Of note, and in stark contrast to the highly polymorphic nature of the MHC class I and class II complexes that restrict αβ T cell responses, the vast majority of γδ T cell ligands reported thus far are non-polymorphic in nature.

3.1. Recognition of MHC-related molecules

Most research on γδ T cells so far has used methodologies that were originally developed and successfully applied to αβ T cells, such as immunisations of mice with MHC-mismatched cells, utilisation of transfectant APCs expressing defined antigen-presenting molecules and stainings with antigen-loaded tetramers. Perhaps not surprisingly, such approaches have led to the identification of γδ T cell clones and receptors that were reactive with classical and non-classical MHC molecules. The corresponding ligands included structures such as the murine MHC class II molecules I-E^k and I-A^d [53,54], as well as the MHC class Ib molecules T10/T22 [55,56] and Qa-1 [57] in the mouse, and MICA in humans [58] (Fig. 1).

A number of investigators also characterised CD1-restricted γδ T cells in the mouse [59] and in humans [60–66], including a peculiar T cell clone expressing a δ/αβ TCR [67]. These reports have greatly advanced our understanding of γδ T cell responses in autoimmunity and infection, and may be taken as indication that a considerable proportion of γδ T cells is reactive to MHC and MHC-related molecules [52]. However, it is important to bear in mind that most of these discoveries were based on preconceived ideas using defined ligands to identify the corresponding TCRs. Nevertheless, the importance of MHC-related molecules has been underlined further by the recent identification of γδ T cell clones recognising endothelial protein C receptor (EPCR) [68], HLA-B*5802 [69] and β$_2$-microglobulin-free HLA heavy chain [70] (Fig. 1).

Unexpectedly, many γδ T cell responses to MHC-like molecules turned out not to be strictly dependent on the presentation of specific peptidic or non-peptidic epitopes, unlike the fine-tuned

Fig. 2. Chemical structures of low molecular weight molecules recognised by γδ T cells. Examples include haptens and peptides that may bind the γδ TCR directly; 'phosphoantigens' that are recognised in the context of BTN3; and different classes of lipids that are presented by CD1c and CD1d.

recognition of antigens presented to αβ T cells in the context of MHC class I and II, MR1 and CD1. This is certainly the case for I-E^k [54], T10/T22 [56], MICA [58] and EPCR [68], neither of which appear to present antigens to the corresponding γδ TCRs. The

case of Qa-1 is less clear, with indirect evidence pointing toward a possible presentation of antigenic peptides [71]. With regard to CD1-restricted γδ T cell responses, a range of phospholipids and glycolipids has been shown to activate certain γδ T cell sub-

sets. Such compounds include phosphomycoketide and dipalmitoyl phosphatidylcholine in association with CD1c [62,66], as well as the CD1d-presented molecules cardiolipin in mice [59], and phosphatidylethanolamine, sulfatide and α-galactosylceramide in humans [61–64,67] (Fig. 2). However, despite strong responses towards defined phospholipids, most CD1-restricted γδ T cells also respond with lower affinities to 'empty' CD1 molecules, which may or may not present yet unknown self lipids [60,65].

These findings highlight a remarkable dichotomy between γδ T cells and αβ T cells, where αβ TCRs recognise truly presented antigens in the classical sense while γδ TCRs may often respond to stress-induced 'empty' or non-presenting MHC-like molecules. Of note, in contrast to the invariant mouse Vγ5/Vδ1 and Vγ6/Vδ1 TCRs and CMV-reactive human Vγ8/Vδ1 TCR described above, most γδ TCRs recognising MHC-related molecules appear to contain N additions in their CDR3 regions, and the corresponding γδ T cell populations are typically rare [39,53,64].

3.2. Antibody-like recognition of surface-associated and soluble structures

Early reports on the responsiveness to MHC-like molecules by certain γδ T cell receptors were soon to be paralleled by the discovery of soluble and surface-bound proteins that appeared to bind directly to murine and human γδ TCRs. These findings in fact led some authors to liken the recognition of these potential ligands by γδ T cells to the way immunoglobulins recognise their targets antigens, which typically constitute three-dimensional epitopes on larger molecules [72]. The prime example of a protein that is recognised directly by γδ T cells, in the absence of APCs, is the herpes simplex virus glycoprotein I (HSV-gI) that specifically activates a murine Vγ2/Vδ8 T cell clone and may thus contribute to the γδ T cell-mediated protection against HSV infection in mice [73] (Fig. 1). As with HSV-gI specific γδ T cells, the responsiveness of an autoreactive human Vγ3/Vδ2 T cell clone from a polymyositis lesion toward histidyl-tRNA synthetase is directed in an antibody-like manner against a conformational epitope of the target antigen [74,75]. Of note, this Vγ3/Vδ2 TCR also cross-reacts with bacterial aminoacyl-tRNA synthetases and *E. coli* translation initiation factor 1.

The human MutS homologue 2 (hMSH2), a nuclear DNA mismatch repair protein that can be expressed ectopically on tumour cells, represents another potential protein ligand for certain human γδ T cells [76]. However, as hMSH2 appears to interact with both the γδ TCR and NKG2D the precise role of the γδ TCR in recognising tumour-associated hMSH2 remains to be resolved. More recent examples of potentially stress and infection-regulated self proteins include annexin A2 and ephrin receptor A2 (EphA2), which are recognised by human Vδ2[neg] T cell clones derived from CMV infected individuals [69,70,77] (Fig. 1).

Finally, phycoerythrin (PE) is a fluorescent molecule in cyanobacteria and red algae that is recognised by a small proportion of γδ T cells in humans, mice and cattle [78]. Although there may not be a relevant pathogen that produces PE, it is the first described ligand that activates γδ T cells in different species, albeit with no apparent sequence similarity between PE-specific γδ TCRs in humans and mice. PE is also the first soluble protein that allows to conveniently track and analyse antigen-specific γδ T cells in the mouse and therefore has enormous potential in experimental models.

In addition to larger proteins, some γδ T cells also recognise smaller molecules, which are believed to bind directly to the TCR, in the absence of APCs [79]. One such candidate is the insulin B:9-23 peptide that is recognised in a dimerised form by murine γδ T cells, possibly as a conformational structure rather than a linearised peptide sequence [80] (Fig. 1). Further self and non-self molecules that

have been described to activate human, murine or bovine γδ T cells include peptides derived from heat shock proteins, mycobacterial antigens, tetanus toxin, listeriolysin O and immunoglobulin λ light chain [79,81], as well as the haptens cyanine 3 and 4-hydroxy-3-nitrophenyl acetyl [82] (Fig. 2). In the majority of cases, especially for endogenous self peptides, the physiological context leading to the availability of such soluble molecules as potential ligands for the γδ TCR remains to be elucidated.

3.3. The peculiar case of phosphoantigens

The majority of human and primate Vγ9/Vδ2 T cells responds rapidly to small phosphorylated molecules *in vitro*, often referred to as 'phosphoantigens' [3]. By far the most potent of these compounds is the microbial metabolite (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), which is produced by many Gram-positive and Gram-negative bacteria as well as malaria parasites and *Toxoplasma gondii* [3,36] (Fig. 1). Other compounds with activity on Vγ9/Vδ2 T cells, albeit at levels that can be several magnitudes above the minimum effective concentration of HMB-PP, include the ubiquitous metabolites isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are present in all prokaryotes and eukaryotes, and related synthetic molecules such as monoethyl phosphate, bromohydrin pyrophosphate (Phosphostim) and a pyrophosphonate analogue of HMB-PP (Picostim) [3,83] (Fig. 2). Furthermore, the reactivity of Vγ9/Vδ2 T cells toward aminobisphosphonate drugs such as alendronate, pamidronate and zoledronate and toward natural and synthetic alkylamines can be explained by the intracellular accumulation of IPP, DMAPP and byproducts such as the AMP conjugate of IPP, ApppI, thereby rendering treated target cells susceptible to recognition by Vγ9/Vδ2 T cells [83–85]. In addition to its intracellular accumulation, IPP can be released by zoledronate-treated dendritic cells into the microenvironment where it becomes available to uptake by other cells and/or activation of γδ T cells [83,86]. But are 'phosphoantigens' true γδ TCR ligands? Originally thought to bind to the γδ TCR directly [87] and possibly 'presented' in the context of accessory proteins including mitochondrial F1-ATPase [88], the recent discovery of butyrophilin-3 (BTN3) as crucial restricting element rather points toward an indirect recognition of 'phosphoantigens' [89]. Of note, the presence of Vγ9/Vδ2 TCRs may not be restricted to higher primates. While being absent in mice, rats, rabbits, cattle and other farm animals, recent findings suggest that functional Vγ9/Vδ2 T cells and the reactivity toward 'phosphoantigens', alongside BTN3, may also be present in alpacas [90]. Such observations indicate that this microbe-responsive γδ T cell population may have arisen early during evolution of placental mammals and later on been lost in various groups including rodents [91].

3.4. The role of butyrophilins

Recent studies demonstrated that the BTN3 isoform, BTN3A1, is essential for Vγ9/Vδ2 T cell responses to HMB-PP, IPP and aminobisphosphonate-treated cells [89,92]. Initially proposed as a 'phosphoantigen' presenting molecule [92], a growing body of biochemical and structural evidence identified an unexpected 'phosphoantigen' binding site in the intracellular B30.2 (PRY/SPRY) domain of BTN3A1 [93–95]. In essence, BTN3A1 appears to convert a peculiar microbial (HMB-PP) or stress-related (IPP) non-peptidic signal into a rather common biological phenomenon, namely the recognition of a cell surface-associated and possibly conformational epitope that is somehow sensed by Vγ9/Vδ2 T cells [98] (Fig. 1). While the related isoforms, BTN3A2 and BTN3A3, are somehow involved in this process [95] the exact mechanism remains to be defined. BTN3 has consequently replaced 'phosphoantigens' as candidate ligand for Vγ9/Vδ2 T cells although it may require

Fig. 3. Physiological context of γδ T cell ligand recognition. (*A*) Recognition of ligands in different physiological settings, ranging from ligand presentation by APCs to recognition of stressed and infected cells and direct binding of soluble molecules. (*B–D*) Overlapping recognition of stress and infection related ligands by γδ T cells and by immune receptors expressed by other cells. Examples for such promiscuous γδ T cell ligands include, but are not limited to, MHC and CD1 family members that are recognised by the TCRs of conventional and unconventional T cells (B); stress ligands such as MICA/B that are recognised by NKG2D on T cells and NK cells (C); and soluble B cell antigens such as PE and targets of autoantibodies such as tRNA synthetases (D). BCR/Ig, B cell receptor/immunoglobulin.

accessory molecules and may not be recognised directly by the Vγ9/Vδ2 TCR [95–99]. Of note, the immunological role of BTN3A1 may extend beyond the regulation of γδ T cell responses [100,101].

The clear role for BTN3 in driving human Vγ9/Vδ2 T cell responses evokes seminal discoveries in other systems amounting to the realisation that the family of butyrophilin-like (BTNL in humans, Btnl in mice) proteins plays a pivotal part in shaping the γδ T cell compartment [102–104]. The best studied Btnl member, Skint-1, is crucially important for the maturation of murine thymocytes and the appearance of Vγ5/Vδ1 DETCs in the epidermis [105,106]. This process requires thymic and epidermal expression of Skint-1, although it is not clear whether Skint-1 indeed constitutes a direct ligand for the Vγ5/Vδ1 TCR [106,107] (Fig. 1). Intriguingly, there may also to be a role for Skint-3 and Skint-9 in modulating DETC function, especially during wound repair [108]. In analogy to the Skint-1 restricted development of Vγ5/Vδ1 T cells in the mouse epidermis, joint expression of the related proteins Btnl1 and Btnl6 by murine enterocytes is required for the extrathymic selection of intestinal Vγ7+ T cells [104]. Similarly, human BTNL3 and BTNL8 appear to jointly induce selective TCR-dependent responses by Vγ4+ T cells derived from the human colon [104].

These groundbreaking findings demonstrate that different butyrophilins influence the development of specific γδ T cell populations characterised by distinct Vγ chains in mice and in humans, and identify a fundamental selection principle that is likely to be applicable to other γδ T cell subsets and other species. How the different members of the butyrophilin family achieve this remains to be elucidated, especially as to whether they bind the γδ TCR directly or merely constitute critical co-factors. The fact that the majority of Btnl and BTNL proteins (with the prominent exception of Skint-1) possess intracellular B30.2 domains also raises the possibility that as yet unknown accessory molecules are involved in shaping the γδ T cell repertoire. B30.2 domains not only sense HMB-PP and IPP in the case of BTN3A1 but also confer pattern recognition receptor-like functions to tripartite motif proteins such as TRIM5α and TRIM21 that are evolutionarily linked to butyrophilins [103,109a]. While the selection of Vγ7+ T cells by Btnl1/Btnl6 appears to be independent of microbial or food antigens [104], the self and non-self metabolites and proteins potentially interacting with butyrophilins clearly deserve closer attention.

4. Context of ligand expression: by a simple twist of fate

4.1. Sensing self, stressed self and non-self

The physiological contexts in which γδ T cell ligands become accessible is key to understand the role of γδ T cells in the immune system. The chemical and conformational structures that γδ T cells respond to cover molecules associated with infection, stressed tissues and tumours as well as with the healthy status, and are far more diverse than the relatively narrow range of MHC and CD1-presented αβ T cell antigens (Fig. 3A). γδ T cells sense these ligands by patrolling blood and endothelial and mucosal surfaces for pathogen pattern recognition, and as tissue-resident cells by monitoring tissue integrity and vitality [4–6,36]. Pathogens may actually influence this tissue monitoring by targeting γδ T cell ligands. In this context, it has recently been shown that human papillomavirus oncoproteins induce a decrease in epidermal Skint1 expression, which is associated with a change in morphology and reduced density of the associated Vγ5/Vδ1 DETC [109b]. Of note, besides the TCR, γδ T cells can also express other activating receptors such as NKG2D, NKp30 and CD16 [110], which may complement or even replace TCR signalling in different contexts. For instance, the role DETCs play in skin immune surveillance is at least in part exerted via recognition of stress-induced NKG2D ligands [111]. The relevance of the majority of the γδ TCR ligands discussed in this review therefore remains ill-defined, especially since many are only recognised by a very small proportion of the total γδ T cell population [55,78], or by seemingly rare γδ T cell clones found in individual patients [68–70,75].

Non-self molecules sensed by human or murine γδ T cells include proteinaceous and non-proteinaceous molecules as diverse as viral HSV-gI [73], algae-derived PE [78], staphylococcal superantigens [112,113], listerolysin and tetanus toxin peptides [79], pollen-derived phosphatidylethanolamine [61], bacterial cardiolipin [59], mycobacterial phosphomycoketide [62] and HMB-PP [36], together with further unidentified microbial compounds [62,114–116]. Bovine γδ T cells recognise a range of antigens derived from *Mycobacterium bovis*, *Leptospira* and *Anaplasma* although the precise role of the γδ TCR in such responses and the contribution of WC1 as co-receptor and pattern recognition receptor requires further characterisation [81,117,118]. Of note, cardiolipin may also derive from the mitochondria of stressed or damaged host cells [59], and the role of HMB-PP may be mimicked by IPP as host-derived self ligand, despite its much lower bioactivity and B30.2 affinity compared to HMB-PP [83,93]. In addition, γδ T cells may respond to both CD1-presented self and non-self lipids [6,51,52], and there appears to be cross-reactivity between bacterial and mammalian heat shock proteins [79] and aminoacyl-tRNA synthetases [75]. The distinction between self and non-self may thus not be as clear-cut as the above list of ligands insinuates, which raises further questions about the physiological context in which the corresponding γδ T cell populations become activated.

It has been proposed that some γδ TCRs can respond to upregulation of 'stress proteins' upon infection, cell transformation or other conditions, although examples of such a recognition mode are limited [4–6,77,119]. Alternatively, ligands may be constitutively expressed, but it is the molecular context that will define their γδ T cell activation potential. For instance, EPCR, the ligand for a γδ T cell clone that was expanded in a CMV infected transplant recipient, is actually not upregulated upon CMV infection [68]. CMV infection rather appears to result in the induction of other factors that, together with EPCR, form a 'multi-molecular stress signature' [68]. Similarly, the γδ TCR of mouse DETCs appears to be continuously activated within the epidermis, suggesting that the corresponding ligand is constitutively expressed by keratinocytes [120]. However, cellular stress may provoke changes in the expression and/or the conformation of the DETC ligand, possibly in conjunction with additional factors [121]. The importance of further co-factors is also underlined by the fact that both BTN3A1 and IPP are ubiquitously expressed by human cells [91,103]. The exact conditions under which endogenous IPP levels may exceed a possible threshold for stressed cells to become stimulatory to Vγ9/Vδ2 T cells whilst preventing autoreactivity toward metabolically active healthy tissues remain to be defined [3,83]. Clearly, γδ T cell responses to self ligands require carefully balanced control mechanisms.

4.2. Implications for pathology and diagnosis

The ability of γδ T cells to sense structures associated with tissue stress, transformation and infection has direct consequences in the clinic. Ligand-dependent γδ T cell responses may contribute to protective immunity against pathogens [73,122] and tumour immune surveillance [76] but may also drive inflammation-related tissue damage [123] and autoimmune disease [124,125]. For instance, IL-17 producing γδ T cells play a pathogenic role in experimental models of psoriasis [126,127], and IL-17[+] Vγ9/Vδ2 T cells and common CDR3γ sequences have been observed in psoriatic lesions of patients [128,129], suggesting ligand-driven local recruitment and/or expansion in the skin. γδ T cells may also drive the pathology in further autoimmune diseases where certain γδ T subpopulations are locally enriched, possibly in response to self ligands such as sulfatide in the case of multiple sclerosis [63,124,130] and histidyl-tRNA synthetase in the case of polymyositis [74,75]. Vice versa, pathogens may target tissue-restricted ligands and thereby affect the corresponding resident γδ T cell subset [109b]. In mice deficient in the autoimmune regulator Aire, which functions as a master transcriptional regulator of thymic gene expression, foetal IL-17[+] Vγ6/Vδ1 T cells are increased and contribute to retinal inflammation and degeneration [28]. Also, immunodeficient patients with mutations in the *AIRE* gene show elevated percentages of Vγ9/Vδ2 T cells producing IL-17 [28]. Notwithstanding this apparent contribution of Aire to immune tolerance by limiting IL-17 production by γδ T cells that are generated in early life in both mice and humans [33,131], it remains unclear whether Aire-dependent effects on γδ T cell ligand expression in the thymus play a role in selecting autoreactive γδ T cells [28]. With respect to cancer, γδ T cells have well established protective roles in tumour surveillance and immunotherapy, in particular because of their potent cytotoxicity and IFN-γ production [4–6]. However, recent studies have also revealed tumour-promoting functions that are linked to IL-17 producing γδ T cells [109b,132]. How much of such protective or detrimental responses are driven by γδ T cell ligands is unclear.

The exquisite specificity of human Vγ9/Vδ2 T cells for microbial derived HMB-PP may be exploitable for diagnostic and prognostic purposes to help identify the causative pathogen in patient samples well before conventional culture results become available [133]. Infections caused by HMB-PP producing organisms tend to be associated with higher frequencies of Vγ9/Vδ2 T cells than infections caused by HMB-PP deficient organisms. This is the case in the blood of patients with acute sepsis [134] but is particularly pronounced at the site of infection [123,135]. A similar diagnostic potential may reside within the unique reactivity of human Vδ2[neg] T cells to CMV infections [136–138]. In particular, longitudinal monitoring of Vδ2[neg] T cell profiles shows promise as prognostic marker for the prediction of CMV infection resolution and treatment responses in kidney transplant recipients [139]. Finally, recent reports suggest that the expansion of certain Vδ clonotypes in patients with acute myeloid leukaemia may correlate with disease outcome [140], although the specificity of those γδ T cell clones remains to be defined.

It is interesting to note that a significant number of γδ T cell ligands are also recognised by other immune receptors (Fig. 3B–D).

Intriguingly, there are cases of autoantibody production and expansion of γδ T cells possessing the same specificity, for instance in patients with multiple sclerosis and polymyositis [63,74,75,124]. Such recognition of the same targets by immunoglobulins and γδ T cells may result from specific γδ T cell help to B cells [141], which is supported by the observation of a considerable overlap between γδ TCR specificities and natural antibodies [142]. The significance of this redundancy for protection and pathology has not been addressed as yet.

4.3. Implications for therapy and vaccination

A better understanding of γδ T cell ligands will ultimately guide the potential application of γδ T cell based therapies in the clinic. The monomorphic nature of γδ T cell ligands and their independence of the underlying MHC haplotype is in fact ideal for vaccine development and 'off the shelf' cellular therapies. However, given the limited numbers of defined ligands with clear disease relevance and the rare nature of the corresponding γδ T cell clones, there is only scarce evidence for a successful stimulation of γδ T cell responses with defined ligands *in vivo* [82,143].

Most progress in this context has been made thanks to the reactivity of human and primate Vγ9/Vδ2 T cells to 'phosphoantigens'. In cynomolgus macaques, stimulation with HMB-PP itself, or with synthetic HMB-PP analogues, induces a strong expansion of Vγ9/Vδ2 T cells in the blood [144] and their accumulation at mucosal sites including the lungs of treated animals, and attenuates local tuberculosis and plague lesions [122,145]. While these findings demonstrate that protective immunity against microbial pathogens can be achieved by directly harnessing γδ T cells, administration of 'phosphoantigens' alongside mycobacterial antigens did not have any adjuvant effect *in vivo* and did not boost concominant vaccine-induced αβ T cell responses [146]. However, activation of Vγ9/Vδ2 T cells did enhance antibody-dependent cell-mediated cytotoxicity in cynomolgus macaques treated with the anti-CD20 depleting antibody rituximab [147]. In humans, Vγ9/Vδ2 T cells can readily be targeted using aminobisphosphonates such as zoledronate, most likely via indirect accumulation of IPP and DMAPP in endocytic cells including monocytes, osteoclasts and tumour cells [132,148–150]. Alternatively, agonist antibodies against BTN3 may specifically sensitise tumour cells to Vγ9/Vδ2 T cell cytotoxicity although this has thus far only been demonstrated in murine xenotransplantation models [151], and the safety of antibodies targeting ubiquitously expressed BTN3 in the body needs to be established in humans. These reports provide proof-of-concept evidence that γδ T cell responses can be manipulated efficiently if the mode of recognition is known. It will now be interesting to test whether other ligands are similarly capable of stimulating distinct γδ T cell subpopulations *in vivo*. Of note, once activated and/or expanded, the anti-tumour potential of γδ T cells may at least in part depend on their recognition of tumour targets via NKG2D and other natural killer receptors, and the contribution of γδ TCR ligands especially in patients receiving adoptively transferred γδ T cells is unclear as yet [132,148,149].

In other scenarios, specific targeting of γδ T cell ligands in the clinic may allow a suppression of excessive γδ T cell-driven inflammation in infectious or autoimmune diseases. For instance, anti-BTN3 antibodies effectively abrogate Vγ9/Vδ2 T cell responses to microbial pathogens and may thus be able to limit fibrotic scarring of local tissues in vulnerable patient groups [123]. A similar neutralisation of inappropriate Vγ9/Vδ2 T cell responses may be achieved by using TCR-specific variable domains of naturally occurring H chain-only antibodies (nanobodies) [99]. It is thus conceivable that specific masking of stress-induced and/or disease-specific γδ T cell ligands can reduce the recognition of target tissues by pro-inflammatory γδ T cells, which may block the detrimental role these cells can play in autoimmune disorders, transplantation and ischemia-reperfusion injury [152–154].

5. Outlook: there must be some way out of here

The past few years have seen a wealth of data regarding the TCR repertoires of distinct γδ T cell populations in health and disease and a growing list of confirmed and proposed ligands in different species [6,49–52]. Yet, the relevance of the often restricted TCR usage and the chemical diversity in γδ T cell ligands remain largely unclear, and only few structural studies have confirmed definite ligand recognition by the TCR [56,63,64]. There are also open questions pertaining to the specificity of the γδ TCR and the role their ligands play in thymic selection, homeostasis and disease. Moreover, instead of recognising a single ligand, it is conceivable that γδ T cells may show the same cross-reactivity towards a considerable number of different ligands that is well-established for αβ T cells [155]. The existence of multiple specificities of self and non-self reactive γδ TCRs has been discussed before [50], albeit the implications of such a phenomenon for the thymic selection of cross-reactive γδ TCRs and the prevention of potentially autoaggressive responses remain to be addressed.

Most importantly, there is no unbiased approach to identify novel ligands and potential restriction elements. For instance, the extent of γδ TCRs that are restricted by MHC-like molecules is not clear. Whilst a proportion of γδ T cells can indeed be stained with tetramers and respond to known and unknown ligands [52], the identification of CD1 restricted γδ TCRs may ultimately be the result of a technological bias and may not be representative of the γδ TCR repertoire as a whole. This caveat notwithstanding, tetramer-positive γδ T cells may actually be enriched in particular tissues such as the liver and are likely to play a prominent role *in vivo* [156]. Another bias may inevitably be introduced during prolonged cloning procedures that select for clones with high proliferative capacity rather than clones with relevant effector function *in vivo*. Similarly, approaches to screen infection-associated γδ TCRs based on their cross-reactivity with transformed and stressed cells may eventually only yield self ligands whilst ignoring foreign structures [68]. The inherent limitations of current methodologies call for innovative, unsupervised methods that cover the breadth of possible ligands.

High-throughput sequencing has transformed our ability to examine antigen receptor repertoires, but this technology is only starting to be applied to γδ T cell clonotyping [22,31,34,35,129]. It is expected that in-depth analyses of CDR3γ and CDR3δ repertoires of *ex vivo* samples will provide a more unbiased insight into ligand-driven γδ T cell responses during development and towards stress-related and infectious stimuli, as well as into the role of innate-like, invariant and public γδ TCR sequences [22,31,33–35,40]. γδ TCRs that are of demonstrable relevance *in vivo* can then be subjected to ligand identification strategies using functional blocking antibodies [68] or γδ TCR tetramers [121,157]. In addition, single-cell sequencing will greatly expand the current knowledge of the association between particular CDR3 sequences of a γδ T cell and its effector functions including programmed cytokine gene expression [158]. Such approaches will ultimately aid the discovery of the corresponding TCR ligands.

γδ T cells have been conserved as a third type of lymphocyte, alongside αβ T cells and B cells, since the emergence of jawed vertebrates 400 million years ago. The dependence of cellular immunity on a tripartite system of three distinct lymphocyte populations goes back even further as it is already found in lampreys [159]. The existence of profound species-specific differences in TCR repertoires, anatomical locations of γδ T cell subsets and the variable nature of the ligands they respond may therefore reflect strong

evolutionary pressure and rapid adaption within the γδ T cell compartment. Nevertheless, there are molecules that are recognised by γδ T cells across different species and appear to constitute evolutionarily ancient ligands. Such signals include CD1d as restricting element for lipid antigens in humans and mice [6]; phycoerythrin as activator of minor γδ T cell subsets in humans, mice and cattle [78]; and BTN3/HMB-PP, which may activate Vγ9/Vδ2 T cells not only in humans and other primates but also in alpacas [91]. Further work in species other than primates and rodents will help define the relevance of functionally overlapping and divergent γδ T cell responses [90,160,161].

In conclusion, the role of γδ T cells in the immune system has remained enigmatic over the past three decades, mostly due to the paucity of ligands identified so far and their failure to conform to classical αβ T cell-centric models. However, the combination of high through-put sequencing, bespoke animal models and access to well defined patient cohorts and tissue banks is beginning to shine light on one of the remaining blind spots in immunology. Understanding better the molecular nature of γδ T cell ligands and the physiological contexts in which they become available will finally allow the integration of γδ T cell mediated responses into a comprehensive view of innate and adaptive immunity. The times they are a-changin'.

Conflict of interest statement

The authors declare no competing financial interests.

Acknowledgments

Disclaimer: this manuscript was under editorial consideration for 6 months because of a problem with the journal's submission system. The Editors wish to emphasise that the lengthy review process between the original submission on 7 March 2017 and receiving the reviewers' comments on 4 September 2017 was in no way due to potential problems with the quality of the authors' manuscript.

References

[1] J.P. Allison, W.L. Havran, The immunobiology of T cells with invariant γδ antigen receptors, Annu. Rev. Immunol. 9 (1991) 679–705.
[2] W.R. Hein, C.R. Mackay, Prominence of γδ T cells in the ruminant immune system, Immunol. Today 12 (1991) 30–34.
[3] C.T. Morita, C. Jin, G. Sarikonda, H. Wang, Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens, Immunol. Rev. 215 (2007) 59–76.
[4] M. Bonneville, R.L. O'Brien, W.K. Born, γδ T cell effector functions: a blend of innate programming and acquired plasticity, Nat. Rev. Immunol. 10 (2010) 467–478.
[5] P. Vantourout, A. Hayday, Six-of-the-best: unique contributions of γδ T cells to immunology, Nat. Rev. Immunol. 13 (2013) 88–100.
[6] Y.H. Chien, C. Meyer, M. Bonneville, γδ T cells: first line of defense and beyond, Annu. Rev. Immunol. 32 (2014) 121–155.
[7] S. Tonegawa, A. Berns, M. Bonneville, A. Farr, I. Ishida, K. Ito, S. Itohara, C.A. Janeway Jr., O. Kanagawa, M. Katsuk, R. Kubo, J. Lafaille, P. Mombaerts, D. Murphy, N. Nakanishi, Y. Takagaki, L. Van Kaer, S. Verbeek, Diversity

[8] I. Van Rhijn, D.I. Godfrey, J. Rossjohn, D.B. Moody, Lipid and small-molecule display by CD1 and MR1, Nat. Rev. Immunol. 15 (2015) 643–654.
[9] J.J. Miles, D.C. Douek, D.A. Price, Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination, Immunol. Cell. Biol. 89 (2011) 375–387.
[10] S. Gras, S.R. Burrows, S.J. Turner, A.K. Sewell, J. McCluskey, J. Rossjohn, A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned, Immunol. Rev. 250 (2012) 61–81.
[11] S.P. Clark, B. Arden, D. Kabelitz, T.W. Mak, Comparison of human and mouse T-cell receptor variable gene segment subfamilies, Immunogenetics 42 (1995) 531–540.
[12] A.R. Kazen, E.J. Adams, Evolution of the V, D, and J gene segments used in the primate γδ T-cell receptor reveals a dichotomy of conservation and diversity, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) E332–340.
[13] J.S. Heilig, S. Tonegawa, Diversity of murine gamma genes and expression in fetal and adult T lymphocytes, Nature 322 (1986) 836–840.
[14] D. Vermijlen, I. Prinz, Ontogeny of innate T lymphocytes – some innate lymphocytes are more innate than others, Front. Immunol. 5 (2014) 486.
[15] B. Martin, K. Hirota, D.J. Cua, B. Stockinger, M. Veldhoen, Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals, Immunity 31 (2009) 321–330.
[16] C.E. Sutton, S.J. Lalor, C.M. Sweeney, C.F. Brereton, E.C. Lavelle, K.H. Mills, Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity, Immunity 31 (2009) 331–341.
[17] R. O'Brien, N. Jin, Y. Huang, M.K. Aydintug, C. Roark, W. Born, Characteristics of IL-17-producing γδ T cells, Immunity 32 (2010) 1, author reply 2–4.
[18] M. Muñoz-Ruiz, N. Sumaria, D.J. Pennington, B. Silva-Santos, Thymic determinants of γδ T cell differentiation, Trends Immunol. 38 (2017) 336–344.
[19] S.M. Hayes, L. Li, P.E. Love, TCR signal strength influences αβ/γδ lineage fate, Immunity 22 (2005) 583–593.
[20] K.D. Jensen, X. Su, S. Shin, L. Li, S. Youssef, S. Yamasaki, L. Steinman, T. Saito, R.M. Locksley, M.M. Davis, N. Baumgarth, Y.H. Chien, Thymic selection determines γδ T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon γ, Immunity 29 (2008) 90–100.
[21] M. Wencker, G. Turchinovich, R. Di Marco Barros, L. Deban, A. Jandke, A. Cope, A.C. Hayday, Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness, Nat. Immunol. 15 (2014) 80–87.
[22] E. Kashani, L. Föhse, S. Raha, I. Sandrock, L. Oberdörfer, C. Koenecke, S. Suerbaum, S. Weiss, I. Prinz, A clonotypic Vγ4Jγ1/Vδ5Dδ2Jδ1 innate γδ T-cell population restricted to the CCR6+CD27⁻ subset, Nat. Commun. 6 (2015) 6477.
[23] M. Muñoz-Ruiz, J.C. Ribot, A.R. Grosso, N. Gonçalves-Sousa, A. Pamplona, D.J. Pennington, J.R. Regueiro, E. Fernández-Malavé, B. Silva-Santos, TCR signal strength controls thymic differentiation of discrete proinflammatory γδ T cell subsets, Nat. Immunol. 17 (2016) 721–737.
[24] I. Prinz, B. Silva-Santos, D.J. Pennington, Functional development of γδ T cells, Eur. J. Immunol. 43 (2013) 1988–1994.
[25] S.P. Fahl, F. Coffey, D.L. Wiest, Origins of γδ T cell effector subsets: a riddle wrapped in an enigma, J. Immunol. 193 (2014) 4289–4294.
[26] S. Itohara, P. Mombaerts, J. Lafaille, J. Iacomini, A. Nelson, A.R. Clarke, M.L. Hooper, A. Farr, S. Tonegawa, T cell receptor δ gene mutant mice: independent generation of αβ T cells and programmed rearrangements of γδ TCR genes, Cell 72 (1993) 337–348.
[27] N.A. Roberts, A.J. White, W.E. Jenkinson, G. Turchinovich, K. Nakamura, D.R. Withers, F.M. McConnell, G.E. Desanti, C. Benezech, S.M. Parnell, A.F. Cunningham, M. Paolino, J.M. Penninger, A.K. Simon, T. Nitta, I. Ohigashi, Y. Takahama, J.H. Caamano, A.C. Hayday, P.J. Lane, E.J. Jenkinson, G. Anderson, Rank signaling links the development of invariant γδ T cell progenitors and Aire+ medullary epithelium, Immunity 36 (2012) 427–437.
[28] N. Fujikado, A.O. Mann, K. Bansal, K.R. Romito, E.M. Ferre, S.D. Rosenzweig, M.S. Lionakis, C. Benoist, D. Mathis, Aire inhibits the generation of a perinatal population of interleukin-17A-producing γδ T cells to promote immunologic tolerance, Immunity 45 (2016) 999–1012.
[29] M.P. Lefranc, T.H. Rabbitts, A nomenclature to fit the organization of the human T-cell receptor gamma and delta genes, Res. Immunol. 141 (1990) 615–618.
[30] C.M. Parker, V. Groh, H. Band, S.A. Porcelli, C. Morita, M. Fabbi, D. Glass, J.L. Strominger, M.B. Brenner, Evidence for extrathymic changes in the T cell receptor γ/δ repertoire, J. Exp. Med. 171 (1990) 1597–1612.
[31] A.M. Sherwood, C. Desmarais, R.J. Livingston, J. Andriesen, M. Haussler, C.S. Carlson, H. Robins, Deep sequencing of the human TCRγ and TCRβ repertoires suggests that TCRβ rearranges after αβ and γδ T cell commitment, Sci. Transl. Med. 3 (2011) 90ra61.
[32] C. Cairo, C.L. Armstrong, J.S. Cummings, C.O. Deetz, M. Tan, C. Lu, C.E. Davis, C.D. Pauza, Impact of age gender, and race on circulating γδ T cells, Hum. Immunol. 71 (2010) 968–975.

[33] T. Dimova, M. Brouwer, F. Gosselin, J. Tassignon, O. Leo, C. Donner, A. Marchant, D. Vermijlen, Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E556–565.

[34] M.S. Davey, C.R. Willcox, S.P. Joyce, K. Ladell, S.A. Kasatskaya, J.E. McLaren, S. Hunter, M. Salim, F. Mohammed, D.A. Price, D.M. Chudakov, B.E. Willcox, Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance, Nat. Commun. 8 (2017) 14760.

[35] S. Ravens, C. Schultze-Florey, S. Raha, I. Sandrock, M. Drenker, L. Oberdörfer, A. Reinhardt, I. Ravens, M. Beck, R. Geffers, C. von Kaisenberg, M. Heuser, F. Thol, A. Ganser, R. Förster, C. Koenecke, I. Prinz, Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection, Nat. Immunol. 18 (2017) 393–401.

[36] A.R. Liuzzi, J.E. McLaren, D.A. Price, M. Eberl, Early innate responses to pathogens: pattern recognition by unconventional human T-cells, Curr. Opin. Immunol. 36 (2015) 31–37.

[37] C.T. Spencer, G. Abate, A. Blazevic, D.F. Hoft, Only a subset of phosphoantigen-responsive γ9δ2 T cells mediate protective tuberculosis immunity, J. Immunol. 181 (2008) 4471–4484.

[38] J. Déchanet, P. Merville, A. Lim, C. Retière, V. Pitard, X. Lafarge, S. Michelson, C. Méric, M.M. Hallet, P. Kourilsky, L. Potaux, M. Bonneville, J.F. Moreau, Implication of γδ T cells in the human immune response to cytomegalovirus, J. Clin. Invest. 103 (1999) 1437–1449.

[39] F. Halary, V. Pitard, D. Dlubek, R. Krzysiek, H. de la Salle, P. Merville, C. Dromer, D. Emilie, J.F. Moreau, J. Déchanet-Merville, Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells, J. Exp. Med. 201 (2005) 1567–1578.

[40] D. Vermijlen, M. Brouwer, C. Donner, C. Liesnard, M. Tackoen, M. Van Rysselberge, N. Twité, M. Goldman, A. Marchant, F. Willems, Human cytomegalovirus elicits fetal γδ T cell responses in utero, J. Exp. Med. 207 (2010) 807–821.

[41] B.S. Sheridan, P.A. Romagnoli, Q.M. Pham, H.H. Fu, F. Alonzo 3rd, W.D. Schubert, N.E. Freitag, L. Lefrançois, γδ T cells exhibit multifunctional and protective memory in intestinal tissues, Immunity 39 (2013) 184–195.

[42] A.G. Murphy, K.M. O'Keeffe, S.J. Lalor, B.M. Maher, K.H. Mills, R.M. McLoughlin, Staphylococcus aureus infection of mice expands a population of memory γδ T cells that are protective against subsequent infection, J. Immunol. 192 (2014) 3697–3708.

[43] F. Ramírez-Valle, E.E. Gray, J.G. Cyster, Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 8046–8051.

[44] T. Hartwig, S. Pantelyushin, A.L. Croxford, P. Kulig, B. Becher, Dermal IL-17-producing γδ T cells establish long-lived memory in the skin, Eur. J. Immunol. 45 (2015) 3022–3033.

[45] A. Misiak, M.M. Wilk, M. Raverdeau, K.H. Mills, IL-17-producing innate and pathogen-specific tissue resident memory γδ T cells expand in the lungs of Bordetella pertussis-infected mice, J. Immunol. (2016), pii: 1601024.

[46] Y. Shen, D. Zhou, L. Qiu, X. Lai, M. Simon, L. Shen, Z. Kou, Q. Wang, L. Jiang, J. Estep, R. Hunt, M. Clagett, P.K. Sehgal, Y. Li, X. Zeng, C.T. Morita, M.B. Brenner, N.L. Letvin, Z.W. Chen, Adaptive immune response of Vγ2Vδ2+ T cells during mycobacterial infections, Science 295 (2002) 2255–2258.

[47] S.L. Blumerman, C.T. Herzig, F. Wang, P.M. Coussens, C.L. Baldwin, Comparison of gene expression by co-cultured WC1+ γδ and CD4+ αβ T cells exhibiting a recall response to bacterial antigen, Mol. Immunol. 44 (2007) 2023–2035.

[48] S.J. Lalor, R.M. McLoughlin, Memory γδ T cells—Newly appreciated protagonists in infection and immunity, Trends Immunol. 37 (2016) 690–702.

[49] E. Champagne, γδ T cell receptor ligands and modes of antigen recognition, Arch. Immunol. Ther. Exp. 59 (2011) 117–137.

[50] W.K. Born, M.K. Aydintug, R.L. O'Brien, Diversity of γδ T-cell antigens, Cell. Mol. Immunol. 10 (2013) 13–20.

[51] E.J. Adams, S. Gu, A.M. Luoma, Human γδ T cells: evolution and ligand recognition, Cell. Immunol. 296 (2015) 31–40.

[52] D.I. Godfrey, A.P. Uldrich, J. McCluskey, J. Rossjohn, D.B. Moody, The burgeoning family of unconventional T cells, Nat. Immunol. 16 (2015) 1114–1123.

[53] L.A. Matis, A.M. Fry, R.Q. Cron, M.M. Cotterman, R.F. Dick, J.A. Bluestone, Structure and specificity of a class II MHC alloreactive γδ T cell receptor heterodimer, Science 245 (1989) 746–749.

[54] H. Schild, N. Mavaddat, C. Litzenberger, E.W. Ehrich, M.M. Davis, J.A. Bluestone, L. Matis, R.K. Draper, Y.H. Chien, The nature of major histocompatibility complex recognition by γδ T cells, Cell 76 (1994) 29–37.

[55] M.P. Crowley, A.M. Fahrer, N. Baumgarth, J. Hampl, I. Gutgemann, L. Teyton, Y. Chien, A population of murine γδ T cells that recognize an inducible MHC class Ib molecule, Science 287 (2000) 314–316.

[56] E.J. Adams, Y.H. Chien, K.C. Garcia, Structure of a γδ T cell receptor in complex with the nonclassical MHC T22, Science 308 (2005) 227–231.

[57] D. Vidović, M. Roglić, K. McKune, S. Guerder, C. MacKay, Z. Dembić, Qa-1 restricted recognition of foreign antigen by a γδ T-cell hybridoma, Nature 340 (1989) 646–650.

[58] J. Wu, V. Groh, T. Spies, T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells, J. Immunol. 169 (2002) 1236–1240.

[59] M. Dieudé, H. Striegl, A.J. Tyznik, J. Wang, S.M. Behar, C.A. Piccirillo, J.S. Levine, D.M. Zajonc, J. Rauch, Cardiolipin binds to CD1d and stimulates CD1d-restricted γδ T cells in the normal murine repertoire, J. Immunol. 186 (2011) 4771–4781.

[60] F.M. Spada, E.P. Grant, P.J. Peters, M. Sugita, A. Melián, D.S. Leslie, H.K. Lee, E. van Donselaar, D.A. Hanson, A.M. Krensky, O. Majdic, S.A. Porcelli, C.T. Morita, M.B. Brenner, Self-recognition of CD1 by γ/δ T cells: implications for innate immunity, J. Exp. Med. 191 (2000) 937–948.

[61] A.M. Russano, E. Agea, L. Corazzi, A.D. Postle, G. De Libero, S. Porcelli, F.M. de Benedictis, F. Spinozzi, Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted γδ T cells, J. Allergy Clin. Immunol. 117 (2006) 1178–1184.

[62] A.M. Russano, G. Bassotti, E. Agea, O. Bistoni, A. Mazzocchi, A. Morelli, S.A. Porcelli, F. Spinozzi, CD1-restricted recognition of exogenous and self-lipid antigens by duodenal γδ + T lymphocytes, J.Immunol. 178 (2007) 3620–3626.

[63] A.M. Luoma, C.D. Castro, T. Mayassi, L.A. Bembinster, L. Bai, D. Picard, B. Anderson, L. Scharf, J.E. Kung, L.V. Sibener, P.B. Savage, B. Jabri, A. Bendelac, E.J. Adams, Crystal structure of Vδ1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells, Immunity 39 (2013) 1032–1042.

[64] A.P. Uldrich, J. Le Nours, D.G. Pellicci, N.A. Gherardin, K.G. McPherson, R.T. Lim, O. Patel, T. Beddoe, S. Gras, J. Rossjohn, D.I. Godfrey, CD1d-lipid antigen recognition by the γδ TCR, Nat. Immunol. 14 (2013) 1137–1145.

[65] B.A. Mangan, M.R. Dunne, V.P. O'Reilly, P.J. Dunne, M.A. Exley, D. O'Shea, E. Scotet, A.E. Hogan, D.G. Doherty, CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells, J. Immunol. 191 (2013) 30–34.

[66] S. Roy, D. Ly, C.D. Castro, N.S. Li, A.J. Hawk, J.D. Altman, S.C. Meredith, J.A. Piccirilli, D.B. Moody, E.J. Adams, Molecular analysis of lipid-reactive Vδ1 γδ T cells identified by CD1c tetramers, J. Immunol. 196 (2016) 1933–1942.

[67] D.G. Pellicci, A.P. Uldrich, J. Le Nours, F. Ross, E. Chabrol, S.B. Eckle, R. de Boer, R.T. Lim, K. McPherson, G. Besra, A.R. Howell, L. Moretta, J. McCluskey, M.H. Heemskerk, S. Gras, J. Rossjohn, D.I. Godfrey, The molecular bases of δ/αβ T cell-mediated antigen recognition, J. Exp. Med. 211 (2014) 2599–2615.

[68] C.R. Willcox, V. Pitard, S. Netzer, L. Couzi, M. Salim, T. Silberzahn, J.F. Moreau, A.C. Hayday, B.E. Willcox, J. Déchanet-Merville, Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor, Nat. Immunol. 13 (2012) 872–879.

[69] B. Silva-Santos, W.W. Schamel, P. Fisch, M. Eberl, γδ T-cell conference 2012: close encounters for the fifth time, Eur. J. Immunol. 42 (2012) 3101–3105.

[70] M. Bonneville, Z.W. Chen, J. Déchanet-Merville, M. Eberl, J.J. Fournié, J.M. Jameson, R.D. Lopez, M. Massaia, B. Silva-Santos, Chicago 2014-30 years of γδ T cells, Cell. Immunol. 296 (2015) 3–9.

[71] A. Davies, S. Lopez-Briones, H. Ong, C. O'Neil-Marshall, F.A. Lemonnier, K. Nagaraju, E.S. Metcalf, M.J. Soloski, Infection-induced expansion of a MHC Class Ib-dependent intestinal intraepithelial γδ T cell subset, J. Immunol. 172 (2004) 6828–6837.

[72] Y.H. Chien, R. Jores, γδ T cells: T cells with B-cell-like recognition properties, Curr. Biol. 5 (1995) 1116–1118.

[73] R. Sciammas, J.A. Bluestone, HSV-1 glycoprotein I-reactive TCRγδ cells directly recognize the peptide backbone in a conformationally dependent manner, J. Immunol. 161 (1998) 5187–5192.

[74] K. Dornmair, C.K. Schneider, J. Malotka, G. Dechant, H. Wiendl, R. Hohlfeld, Antigen recognition properties of a Vγ1.3Vδ2-T-cell receptor from a rare variant of polymyositis, J. Neuroimmunol. 152 (2004) 168–175.

[75] J. Bruder, K. Siewert, B. Obermeier, J. Malotka, P. Scheinert, J. Kellermann, T. Ueda, R. Hohlfeld, K. Dornmair, Target specificity of an autoreactive pathogenic human γδ-T cell receptor in myositis, J. Biol. Chem. 287 (2012) 20986–20995.

[76] Y. Dai, H. Chen, L. Mo, L. Cui, W. He, Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity, J. Biol. Chem. 287 (2012) 16812–16819.

[77] R. Marlin, A. Pappalardo, H. Kaminski, C.R. Willcox, V. Pitard, S. Netzer, C. Khairallah, A.M. Lomenech, C. Harly, M. Bonneville, J.F. Moreau, E. Scotet, B.E. Willcox, B. Faustin, J. Déchanet-Merville, Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2, Proc. Natl. Acad. Sci. U.S.A. 114 (2017) 3163–3168.

[78] X. Zeng, Y.L. Wei, J. Huang, E.W. Newell, H. Yu, B.A. Kidd, M.S. Kuhns, R.W. Waters, M.M. Davis, C.T. Weaver, Y.H. Chien, γδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response, Immunity 37 (2012) 524–534.

[79] W.K. Born, L. Zhang, M. Nakayama, N. Jin, J.L. Chain, Y. Huang, M.K. Aydintug, R.L. O'Brien, Peptide antigens for gamma/delta T cells, Cell. Mol. Life Sci. 68 (2011) 2335–2343.

[80] M.K. Aydintug, L. Zhang, C. Wang, D. Liang, J.M. Wands, A.W. Michels, B. Hirsch, B.J. Day, G. Zhang, D. Sun, G.S. Eisenbarth, R.L. O'Brien, W.K. Born, γδ T cells recognize the insulin B:9-23 peptide antigen when it is dimerized through thiol oxidation, Mol. Immunol. 60 (2014) 116–128.

[81] J.L. McGill, R.E. Sacco, C.L. Baldwin, J.C. Telfer, M.V. Palmer, W.R. Waters, Specific recognition of mycobacterial protein and peptide antigens by γδ T cell subsets following infection with virulent Mycobacterium bovis, J. Immunol. 192 (2014) 2756–2769.

[82] X. Zeng, C. Meyer, J. Huang, E.W. Newell, B.A. Kidd, Y.L. Wei, Y.H. Chien, γδ T cells recognize haptens and mount a hapten-specific response, eLife 3 (2014) e03609.

[83] C. Riganti, M. Massaia, M.S. Davey, M. Eberl, Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators? Eur. J. Immunol. 42 (2012) 1668–1676.

[84] H.J. Gober, M. Kistowska, L. Angman, P. Jenö, L. Mori, G. De Libero, Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells, J. Exp. Med. 197 (2003) 163–168.

[85] K. Thompson, J. Rojas-Navea, M.J. Rogers, Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway, Blood 107 (2006) 651–654.

[86] B. Castella, J. Kopecka, P. Sciancalepore, G. Mandili, M. Foglietta, N. Mitro, D. Caruso, F. Novelli, C. Riganti, M. Massaia, The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells, Nat. Commun. 8 (2017) 15663.

[87] T.J. Allison, C.C. Winter, J.J. Fournié, M. Bonneville, D.N. Garboczi, Structure of a human γδ T-cell antigen receptor, Nature 411 (2001) 820–824.

[88] J. Mookerjee-Basu, P. Vantourout, L.O. Martinez, B. Perret, X. Collet, C. Périgaud, S. Peyrottes, E. Champagne, F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vγ9Vδ2T cells, J. Immunol. 184 (2010) 6920–6928.

[89] C. Harly, Y. Guillaume, S. Nedellec, C.M. Peigné, H. Mönkkönen, J. Mönkkönen, J. Li, J. Kuball, E.J. Adams, S. Netzer, J. Déchanet-Merville, A. Léger, T. Herrmann, R. Breathnach, D. Olive, M. Bonneville, E. Scotet, Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset, Blood 120 (2012) 2269–2279.

[90] M.M. Karunakaran, T.W. Göbel, L. Starick, L. Walter, T. Herrmann, Vγ9 and Vδ2 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (Vicugna pacos), Immunogenetics 66 (2014) 243–254.

[91] M.M. Karunakaran, T. Herrmann, The Vγ9Vδ2 T cell antigen receptor and butyrophilin-3 A1: Models of interaction, the possibility of co-evolution, and the case of dendritic epidermal T cells, Front. Immunol. 5 (2014) 648.

[92] S. Vavassori, A. Kumar, G.S. Wan, G.S. Ramanjaneyulu, M. Cavallari, S. El Daker, T. Beddoe, A. Theodossis, N.K. Williams, E. Gostick, D.A. Price, D.U. Soudamini, K.K. Voon, M. Olivo, J. Rossjohn, L. Mori, G. De Libero, Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells, Nat. Immunol. 14 (2013) 908–916.

[93] A. Sandstrom, C.M. Peigné, A. Léger, J.E. Crooks, F. Konczak, M.C. Gesnel, R. Breathnach, M. Bonneville, E. Scotet, E.J. Adams, The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2T cells, Immunity 40 (2014) 490–500.

[94] C.H. Hsiao, X. Lin, R.J. Barney, R.R. Shippy, J. Li, O. Vinogradova, D.F. Wiemer, A.J. Wiemer, Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes, Chem. Biol. 21 (2014) 945–954.

[95] D.A. Rhodes, H.C. Chen, A.J. Price, A.H. Keeble, M.S. Davey, L.C. James, M. Eberl, J. Trowsdale, Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin, J. Immunol. 194 (2015) 2390–2398.

[96] Z. Sebestyen, W. Scheper, A. Vyborova, S. Gu, Z. Rychnavska, M. Schiffler, A. Cleven, C. Chéneau, M. van Noorden, C.M. Peigné, D. Olive, R.J. Lebbink, R. Oostvogels, T. Mutis, G.J. Schuurhuis, E.J. Adams, E. Scotet, J. Kuball, RhoB mediates phosphoantigen recognition by Vγ9Vδ2 T cell receptor, Cell Rep. 15 (2016) 1973–1985.

[97] F. Riaño, M.M. Karunakaran, L. Starick, J. Li, C.J. Scholz, V. Kunzmann, D. Olive, S. Amslinger, T. Herrmann, Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6, Eur. J. Immunol. 44 (2014) 2571–2576.

[98] S. Gu, J.R. Sachleben, C.T. Boughter, W.I. Nawrocka, M.T. Borowska, J.T. Tarrasch, G. Skiniotis, B. Roux, E.J. Adams, Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation, Proc. Natl. Acad. Sci. U. S. A. (2017), http://dx.doi.org/10.1073/pnas.1707547114.

[99] R.C. de Bruin, A.G. Stam, A. Vangone, P.M. van Bergen en Henegouwen, H.M. Verheul, Z. Sebestyén, J. Kuball, A.M. Bonvin, T.D. de Gruijl, H.J. van der Vliet, Prevention of Vé9Vγ2 T cell activation by a Vé9Vγ2V TCR nanobody, J. Immunol. 198 (2017) 308–317.

[100] R. Simone, B. Barbarat, A. Rabellino, G. Icardi, M. Bagnasco, G. Pesce, D. Olive, D. Saverino, Ligation of the BT3 molecules members of the B7 family, enhance the proinflammatory responses of human monocytes and monocyte-derived dendritic cells, Mol. Immunol. 48 (2010) 109–118.

[101] M. Seo, S.O. Lee, J.H. Kim, Y. Hong, S. Kim, Y. Kim, D.H. Min, Y.Y. Kong, J. Shin, K. Ahn, MAP4-regulated dynein-dependent trafficking of BTN3A1 controls the TBK1-IRF3 signaling axis, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 14390–14395.

[102] C. Lebrero-Fernández, J.H. Bergström, T. Pelaseyed, A. Bas-Forsberg, Murine butyrophilin-like 1 and Btnl6 form heteromeric complexes in small intestinal epithelial cells and promote proliferation of local T lymphocytes, Front. Immunol. 7 (2016) 1.

[103] D.A. Rhodes, W. Reith, J. Trowsdale, Regulation of immunity by butyrophilins, Annu. Rev. Immunol. 34 (2016) 151–172.

[104] R. Di Marco Barros, N.A. Roberts, R.J. Dart, P. Vantourout, A. Jandke, O. Nussbaumer, L. Deban, S. Cipolat, R. Hart, M.L. Iannitto, A. Laing, B. Spencer-Dene, P. East, D. Gibbons, P.M. Irving, P. Pereira, U. Steinhoff, A. Hayday, Epithelia use butyrophilin-like molecules to shape organ-specific γδ T cell compartments, Cell 167 (2016) 203–218.

[105] N. Xiong, C. Kang, D.H. Raulet, Positive selection of dendritic epidermal γδ T cell precursors in the fetal thymus determines expression of skin-homing receptors, Immunity 21 (2004) 121–131.

[106] S.D. Barbee, M.J. Woodward, G. Turchinovich, J.J. Mention, J.M. Lewis, L.M. Boyden, R.P. Lifton, R. Tigelaar, A.C. Hayday, Skint-1 is a highly specific, unique selecting component for epidermal T cells, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 3330–3335.

[107] M. Salim, T.J. Knowles, R. Hart, F. Mohammed, M.J. Woodward, C.R. Willcox, M. Overduin, A.C. Hayday, B.E. Willcox, Characterization of a putative receptor binding surface on Skint-1, a critical determinant of dendritic epidermal T cell selection, J. Biol. Chem. 291 (2016) 9310–9321.

[108] B.E. Keyes, S. Liu, A. Asare, S. Naik, J. Levorse, L. Polak, C.P. Lu, M. Nikolova, H.A. Pasolli, E. Fuchs, Impaired epidermal to dendritic T cell signaling slows wound repair in aged skin, Cell 167 (2016) 1323–1338.

[109] (a) D.A. Rhodes, B. de Bono, J. Trowsdale, Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? Immunology 116 (2005) 411–417;
(b) D. Van hede, B. Polese, C. Humblet, A. Wilharm, V. Renoux, E. Dortu, L. de Leval, P. Delvenne, C.J. Desmet, F. Bureau, D. Vermijlen, N. Jacobs, Human papillomavirus oncoproteins induce a reorganization of epithelial-associated γδ T cells promoting tumor formation, Proc. Natl. Acad. Sci. U.S.A. (2017), http://dx.doi.org/10.1073/pnas.1712883114, in press.

[110] S.T. Ribeiro, J.C. Ribot, B. Silva-Santos, Five layers of receptor signaling in γδ T-cell differentiation and activation, Front. Immunol. 6 (2015) 15.

[111] T. Dalessandri, G. Crawford, M. Hayes, R. Castro Seoane, J. Strid, IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin, Nat. Commun. 7 (2016) 12080.

[112] C.J. Rust, F. Verreck, H. Vietor, F. Koning, Specific recognition of staphylococcal enterotoxin A by human T cells bearing receptors with the Vγ9 region, Nature 346 (1990) 572–574.

[113] C.T. Morita, H. Li, J.G. Lamphear, R.R. Rich, J.D. Fraser, R.A. Mariuzza, H.K. Lee, Superantigen recognition by γδ T cells: SEA recognition site for human V(2 T cell receptors, Immunity 14 (2001) 331–344.

[114] M. Xia, D.C. Hesser, P. De, I.G. Sakala, C.T. Spencer, J.S. Kirkwood, G. Abate, D. Chatterjee, K.M. Dobos, D.F. Hoft, A subset of protective γδ2 T cells is activated by novel mycobacterial glycolipid components, Infect. Immun. 84 (2016) 2449–2462.

[115] F. Li, X. Hao, Y. Chen, L. Bai, X. Gao, Z. Lian, H. Wei, R. Sun, Z. Tian, The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner, Nat. Commun. 7 (2017) 13839.

[116] A.J. St Leger, J.V. Desai, R.A. Drummond, A. Kugadas, F. Almaghrabi, P. Silver, K. Raychaudhuri, M. Gadjeva, Y. Iwakura, M.S. Lionakis, R.R. Caspi, An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal γδ T cells, Immunity 47 (2017) 148–158, e5.

[117] J. Holderness, J.F. Hedges, A. Ramstead, M.A. Jutila, Comparative biology of γδ T cell function in humans, mice, and domestic animals, Annu. Rev. Anim. Biosci. 1 (2013) 99–124.

[118] J.C. Telfer, C.L. Baldwin, Bovine γδ T cells and the function of γδ T cell specific WC1 co-receptors, Cell. Immunol. 296 (2015) 76–86.

[119] B. Xu, J.C. Pizarro, M.A. Holmes, C. McBeth, V. Groh, T. Spies, R.K. Strong, Crystal structure of a γδ T-cell receptor specific for the human MHC class I homolog MICA, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 2414–2419.

[120] G. Chodaczek, V. Papanna, M.A. Zal, T. Zal, Body-barrier surveillance by epidermal γδ TCRs, Nat. Immunol. 13 (2012) 272–282.

[121] H.K. Komori, D.A. Witherden, R. Kelly, K. Sendaydiego, J.M. Jameson, L. Teyton, W.L. Havran, Dendritic epidermal γδ T cell ligands are rapidly and locally expressed by keratinocytes following cutaneous wounding, J. Immunol. 188 (2012) 2972–2976.

[122] C.Y. Chen, S. Yao, D. Huang, H. Wei, H. Sicard, G. Zeng, H. Jomaa, M.H. Larsen, W.R. Jacobs Jr., R. Wang, N. Letvin, Y. Shen, L. Qiu, L. Shen, Z.W. Chen, Phosphoantigen/IL2 expansion and differentiation of Vγ9Vδ2 T cells increase resistance to tuberculosis in nonhuman primates, PLoS Pathog. 9 (2013) e1003501.

[123] A.R. Liuzzi, A. Kift-Morgan, M. Lopez-Anton, I.M. Friberg, J. Zhang, A.C. Brook, G.W. Roberts, K.L. Donovan, C.S. Colmont, M.A. Toleman, T. Bowen, D.W. Johnson, N. Topley, B. Moser, D.J. Fraser, M. Eberl, Unconventional human T cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodelling, J. Immunol. 197 (2016) 2195–2207.

[124] K.W. Wucherpfennig, J. Newcombe, H. Li, C. Keddy, M.L. Cuzner, D.A. Hafler, γδ T-cell receptor repertoire in acute multiple sclerosis lesions, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4588–4592.

[125] L. Bai, D. Picard, B. Anderson, V. Chaudhary, A. Luoma, B. Jabri, E.J. Adams, P.B. Savage, A. Bendelac, The majority of CD1d-sulfatide-specific T cells in human blood use a semi-invariant Vδ1 TCR, Eur. J. Immunol. 42 (2012) 2505–2510.

[126] Y. Cai, F. Xue, C. Fleming, J. Yang, C. Ding, Y. Ma, M. Liu, H.G. Zhang, J. Zheng, N. Xiong, J. Yan, Differential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammation, Nat. Commun. 5 (2014) 3986.

[127] F. Ramírez-Valle, E.E. Gray, J.G. Cyster, Inflammation induces dermal Vγ4+ γδ T17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 8046–8051.

[128] U. Laggner, P. Di Meglio, G.K. Perera, C. Hundhausen, K.E. Lacy, N. Ali, C.H. Smith, A.C. Hayday, B.J. Nickoloff, F.O. Nestle, Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis, J. Immunol. 187 (2011) 2783–2793.

[129] J.L. Harden, D. Hamm, N. Gulati, M.A. Lowes, J.G. Krueger, Deep sequencing of the T-cell receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis, F1000Res 4 (2015) 460.

[130] A.K. Singh, L. Novakova, M. Axelsson, C. Malmeström, H. Zetterberg, J. Lycke, S.L. Cardell, High interferon-γ uniquely in Vδ1 T cells correlates with markers of inflammation and axonal damage in early multiple sclerosis, Front. Immunol. 8 (2017) 260.

[131] J.D. Haas, S. Ravens, S. Düber, I. Sandrock, E. Oberdörfer, E. Kashani, V. Chennupati, L. Föhse, R. Naumann, S. Weiss, A. Krueger, R. Förster, I. Prinz, Development of interleukin-17-producing γδ T cells is restricted to a functional embryonic wave, Immunity 37 (2012) 48–59.

[132] B. Silva-Santos, K. Serre, H. Norell, γδ T cells in cancer, Nat. Rev. Immunol. 15 (2015) 683–691.

[133] M. Eberl, I.M. Friberg, A.R. Liuzzi, M.P. Morgan, N. Topley, Pathogen-specific immune fingerprints during acute infection: the diagnostic potential of human γδ T-cells, Front. Immunol. 5 (2014) 572.

[134] M.S. Davey, M.P. Morgan, A.R. Liuzzi, C.J. Tyler, M.W. Khan, T. Szakmany, J.E. Hall, B. Moser, M. Eberl, Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells, J. Immunol. 193 (2014) 3704–3716.

[135] C.Y. Lin, G.W. Roberts, A. Kift-Morgan, K.L. Donovan, N. Topley, M. Eberl, Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients, J. Am. Soc. Nephrol. 24 (2013) 2002–2009.

[136] V. Pitard, D. Roumanes, X. Lafarge, L. Couzi, I. Garrigue, M.E. Lafon, P. Merville, J.F. Moreau, J. Déchanet-Merville, Long-term expansion of effector/memory Vδ2- γδ T cells is a specific blood signature of CMV infection, Blood 112 (2008) 1317–1324.

[137] L. Couzi, Y. Levaillant, A. Jamai, V. Pitard, R. Lassalle, K. Martin, I. Garrigue, O. Hawchar, F. Siberchicot, N. Moore, J.F. Moreau, J. Dechanet-Merville, P. Merville, Cytomegalovirus-induced γδ T cells associate with reduced cancer risk after kidney transplantation, J. Am Soc. Nephrol. 21 (2010) 181–188.

[138] R. Rovito, M.J. Korndewal, M.C. van Zelm, D. Ziagkos, E. Wessels, M. van der Burg, A.C. Kroes, A.W. Langerak, A.C. Vossen, BT and B cell markers in dried blood spots of neonates with congenital cytomegalovirus infection: B cell numbers at birth are associated with long-term outcomes, J. Immunol. 198 (2017) 102–109.

[139] H. Kaminski, I. Garrigue, L. Couzi, B. Taton, T. Bachelet, J.F. Moreau, J. Déchanet-Merville, R. Thiébaut, P. Merville, Surveillance of γδ T cells predicts cytomegalovirus infection resolution in kidney transplants, J. Am. Soc. Nephrol. 27 (2016) 637–645.

[140] Z. Jin, Q. Luo, S. Lu, X. Wang, Z. He, J. Lai, S. Chen, L. Yang, X. Wu, Y. Li, Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia, J. Hematol. Oncol. 9 (2016) 126.

[141] C.J. Tyler, D.G. Doherty, B. Moser, M. Eberl, Human Vγ9Vδ2 T cells: innate adaptors of the immune system, Cell. Immunol. 296 (2015) 10–21.

[142] W.K. Born, Y. Huang, W. Zeng, R.M. Torres, R.L. O'Brien, A special connection between γδ T cells and natural antibodies? Arch. Immunol. Ther. Exp. 64 (2016) 455–462.

[143] Y.X. Fu, R. Cranfill, M. Vollmer, R. Van Der Zee, R.L. O'Brien, W. Born, In vivo response of murine γδ T cells to a heat shock protein-derived peptide, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 322–326.

[144] H. Sicard, S. Ingoure, B. Luciani, C. Serraz, J.J. Fournié, M. Bonneville, J. Tiollier, F. Romagné, In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model, J. Immunol. 175 (2005) 5471–5480.

[145] D. Huang, C.Y. Chen, Z. Ali, L. Shao, L. Shen, H.A. Lockman, R.E. Barnewall, C. Sabourin, J. Eestep, A. Reichenberg, M. Hintz, H. Jomaa, R. Wang, Z.W. Chen, Antigen-specific Vγ9Vδ2 T effector cells confer homeostatic protection against pneumonic plaque lesions, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 7553–7558.

[146] D. Cendron, S. Ingoure, A. Martino, R. Casetti, F. Horand, F. Romagné, H. Sicard, J.J. Fournié, F. Poccia, A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates, Eur. J. Immunol. 37 (2007) 549–565.

[147] J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.F. Lepage, A. Quillet-Mary, L. Ysebaert, G. Laurent, H. Sicard, J.J. Fournié, Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies, Blood 113 (2009) 4875–4884.

[148] J.P. Fisher, J. Heuijerjans, M. Yan, K. Gustafsson, J. Anderson, γδ T cells for cancer immunotherapy: a systematic review of clinical trials, OncoImmunology 3 (2014) e27572.

[149] J.J. Fournié, H. Sicard, M. Poupot, C. Bezombes, A. Blanc, F. Romagné, L. Ysebaert, G. Laurent, What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell. Mol. Immunol. 10 (2013) 35–41.

[150] M.R. Zocchi, D. Costa, R. Venè, F. Tosetti, N. Ferrari, S. Minghelli, R. Benelli, S. Scabini, E. Romairone, S. Catellani, A. Profumo, A. Poggi, Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity, OncoImmunology 6 (2017) e1278099.

[151] A. Benyamine, A. Le Roy, E. Mamessier, J. Gertner-Dardenne, C. Castanier, F. Orlanducci, L. Pouyet, A. Goubard, Y. Collette, N. Vey, E. Scotet, R. Castellano, D. Olive, BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia, OncoImmunology 5 (2016) e1146843.

[152] Y. Maeda, P. Reddy, K.P. Lowler, C. Liu, D.K. Bishop, J.L. Ferrara, Critical role of host γδ T cells in experimental acute graft-versus-host disease, Blood 106 (2005) 749–755.

[153] M. Gelderblom, P. Arunachalam, T. Magnus, γδ T cells as early sensors of tissue damage and mediators of secondary neurodegeneration, Front. Cell. Neurosci. 8 (2014) 368.

[154] N.E. McCarthy, C.R. Hedin, T.J. Sanders, P. Amon, I. Hoti, I. Ayada, V. Baji, E.M. Giles, M. Wildemann, Z. Bashir, K. Whelan, I. Sanderson, J.O. Lindsay, A.J. Stagg, Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn's disease, J. Clin. Invest. 125 (2015) 3215–3225.

[155] A.K. Sewell, Why must T cells be cross-reactive? Nat. Rev. Immunol. 12 (2012) 669–677.

[156] F. Li, X. Hao, Y. Chen, L. Bai, X. Gao, Z. Lian, H. Wei, R. Sun, Z. Tian, The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner, Nat. Commun. 7 (2017) 13839.

[157] M.K. Aydintug, C.L. Roark, X. Yin, J.M. Wands, W.K. Born, R.L. O'Brien, Detection of cell surface ligands for the γδ TCR using soluble TCRs, J. Immunol. 172 (2004) 4167–4175.

[158] Y.L. Wei, A. Han, J. Glanville, F. Fang, L.A. Zuniga, J.S. Lee, D.J. Cua, Y.H. Chien, A highly focused antigen receptor repertoire characterizes γδ T cells that are poised to make IL-17 rapidly in naive animals, Front. Immunol. 6 (2015) 118.

[159] M. Hirano, P. Guo, N. McCurley, M. Schorpp, S. Das, T. Boehm, M.D. Cooper, Evolutionary implications of a third lymphocyte lineage in lampreys, Nature 501 (2013) 435–438.

[160] G. Linguiti, R. Antonacci, G. Tasco, F. Grande, R. Casadio, S. Massari, V. Castelli, A. Consiglio, M.P. Lefranc, S. Ciccarese, Genomic and expression analyses of Tursiops truncatus T cell receptor gamma (TRG) and alpha/delta (TRA/TRD) loci reveal a similar basic public γδ repertoire in dolphin and human, BMC Genomics 17 (2016) 634.

[161] F. Wan, C. Hu, J. Ma, K. Gao, L. Xiang, J. Shao, Characterization of γδ T cells from zebrafish provides insights into their important role in adaptive humoral immunity, Front. Immunol. 7 (2017) 675.